VivoSeq
Other

Benign Prostatic Hyperplasia

94

Pipeline Programs↗

15

Active Trials↗

40

Companies Involved↗

Benign Prostatic Hyperplasia is a moderately active landscape with 94 programs across 40 companies. The most active players are Light Sciences Oncology, Ferring, Ausio Pharmaceuticals, LLC. 32 therapies are approved with 22 more in late-stage development.

Intelligence

Pipeline Metrics

Competitive Density

69/100

Pipeline Velocity

27/100

Mech. Concentration

16/100

Completion Rate

89/100

Attrition Rate

9/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

L

Light Sciences Oncology

1 program

Phase 2Ferring logo

Ferring

1 program

Phase 2A

Ausio Pharmaceuticals, LLC

1 program

Phase 2Spectrum Pharmaceuticals, Inc logo

Spectrum Pharmaceuticals, Inc

1 program

Phase 2V

Vitae Pharmaceuticals Inc., an Allergan affiliate

1 program

Phase 2R

Revance Therapeutics, Inc.

1 program

Phase 2

Pipeline

Programs by Phase

Analysis

Modality Breakdown

99%

Small molecule

109 of 110 classified programs — the dominant modality here.

1%ALL OTHERSMonoclonal antibody1<1%

Small molecule leads; the ring shows all 110 classified programs, each share of the total. Modality classified for 100% of 111 pipeline programs.

Analysis

Trial Status

145

clinical trials

Completed107 · 74%
Unknown status10 · 7%
Terminated9 · 6%
Recruiting7 · 5%
Not yet recruiting6 · 4%
Withdrawn4 · 3%
Other2 · 1%

Clinical Trials

Trial Activity

145 trials

Medications for Lower Urinary Tract Symptoms Secondary to Benign Prostatic Hyperplasia
Recruiting·TTanta University·Phase 3·NCT06491108·150 enrolled
Effetivity of Dutasteride and Aloe Vera Extract Combination on Angiogenesis and Obstruction on Benign Prostatic Hyperplasia
Recruiting·UUniversitas Diponegoro·Phase 1·NCT07065682·84 enrolled
The Efficacy and Safety of Silodosin Singly or Combined With Ningmitai Capsules in the Treatment of Benign Prostatic Hyperplasia
Recruiting·XXintian Pharmaceutical·Phase 4·NCT05551221·312 enrolled
Study on the Effectiveness of Tranilast in the Treatment of Medium to Large Volume Benign Prostatic Hyperplasia
Recruiting·—·Phase 1·NCT06689514·30 enrolled
New Treatment Strategies and Epigenetic Biomarker for Management of Benign Prostatic Hyperplasia
Recruiting·—·Phase 2·NCT06944145·242 enrolled
The Safety and Effectiveness of Steep Pulse Therapy System for the Ablation of Benign Prostatic Hyperplasia
Recruiting·FFirst Affiliated Hospital of Zhejiang University·N/A·NCT06867315·10 enrolled
Safety and Effectiveness of the Optilume® BPH Catheter System in a Post-Market Study
Recruiting·UUrotronic Inc.·Preclinical·NCT06312722·92 enrolled
A Prospective Multi-site Registry of Real-world Experience With the OPtilume™ BPH Catheter SystEm for Treatment of Men eXperiencing Symptomatic BPH
Active, not recruiting·UUrotronic Inc.·N/A·NCT06560476·500 enrolled
Efficacy and Safety of Two Fixed-dose Combinations in Men with Lower Urinary Tract Symptoms Associated with Benign Prostatic Hyperplasia. (BENIPRO)
Not yet recruiting·EEurofarma Laboratorios S.A.·Phase 3·NCT06546735·816 enrolled
A Phase III Clinical Study of H077 Sustained-Release Tablets Compared With Silodosin Capsules in the Treatment of Benign Prostatic Hyperplasia
Not yet recruiting·SShanghai Huilun Pharmaceutical Co., Ltd.·Phase 3·NCT07146386·728 enrolled
Efficacy and Safety of the DTT106 in the Treatment of Erectile Dysfunction Associated With Benign Prostatic Hyperplasia
Not yet recruiting·EEMS·Phase 3·NCT06264414·262 enrolled
Efficacy/ Safety of Product DNN.65.21.005 in Patients With Benign Prostatic Hyperplasia
Not yet recruiting·AAche Laboratorios Farmaceuticos S.A.·Phase 3·NCT07270432·218 enrolled
UNVEIL-BPO Median Lobe Study: An International Multicenter Evaluation of Selective Median Lobe Resection and Enucleation
Not yet recruiting·NNecmettin Erbakan University·N/A·NCT07699718·420 enrolled
Evaluation of the Effects of Preoperative Anxiety and Surgical Fear on Postoperative Functional Outcomes and Patient Satisfaction in Patients Scheduled for HoLEP and TURP Due to Benign Prostatic Hyperplasia: A Prospective Observational Study
Not yet recruiting·HHitit University·N/A·NCT07663097·80 enrolled
A Pilot Study Of The ALPFA Benign Prostatic Hyperplasia (BPH) Pulsed Field Ablation (PFA) System In Men With Symptomatic Benign Prostatic Hyperplasia
Enrolling by invitation·AALPFA Medical·Preclinical·NCT06965582·100 enrolled
Page 1 of 10

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)